Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month fiscal 2026 financial results announced for periods ended September 30, 2026.
LIFECORE BIOMEDICAL, INC. DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month fiscal 2026 financial results announced for periods ended September 30, 2026
- Results press release furnished as Exhibit 99.1, providing the substantive financial details
- Investor focus: quarterly performance, year-to-date trends, and management outlook in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $25.3M, down 18.6%; nine-month revenue $82.7M, down 21.8%, signaling continued demand weakness
- CDMO revenue fell 18% in Q3 and 29% year-to-date, the primary driver of sales deterioration
- Q3 gross margin improved to 27.0% from 25.0%, while nine-month margin declined to 28.3% from 32.8%
- Net loss widened to $40.1M, driven largely by a $31.3M fair-value loss on related-party debt derivatives
- Two technology-transfer wins and three development programs expand the pipeline, with new revenue expected beginning in 2027; liquidity totaled $38.0M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIFECORE BIOMEDICAL, INC. DE 8-K filings
Get the next LFCR 8-K as it lands
Follow LFCR for push alerts, or ask the research agent what this filing means.